The DOI matches its Crossref record.
Bivalirudin
Abstract
Summary: Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention (PCI). Bivalirudin has a unique pharmacologic profile: unlike other marketed DTIs, it undergoes predominant non-organ elimination (proteolysis), and has the shortest half-life (~25 min). Its affinity for thrombin is intermediate between that of lepirudin (highest) and argatroban (lowest) — this helps explain why it interferes with functional clotting assays to an extent intermediate between that achieved by these two other DTIs. This effect is best known for the PT (INR) — higher affinity for thrombin corresponds to lower molar DTI requirements to prolong the APTT; in turn, lower concentrations required for APTT prolongation (and, presumably, in-vivo effect) result in reduced PT (INR) prolongation. Bivalirudin is primarily used for its first FDA-approved indication, namely anticoagulation during percutaneous transluminal coronary angioplasty ("balloon angioplasty"), the most frequent type of PCI. Bivalirudin is also indicated for PCI with provisional use of glycoprotein IIb/IIIa antagonist therapy, and for patients with, or at risk of, heparin-induced thrombocytopenia (HIT), or HIT with thrombosis syndrome (HITTS), undergoing PCI. The bivalirudin development program has used a "quadruple" endpoint comprising a "triple" efficacy endpoint plus major bleeding —this approach anticipated the subsequent emphasis on strategies to improve clinical outcomes through bleeding reduction. Besides summarizing the key trials evaluating bivalirudin use for acute coronary syndrome (especially employing PCI), we review also the studies of bivalirudin as anticoagulant for "on-" and "off-pump" cardiac surgery, including both HIT and non-HIT situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Pagano, D., Milojevic, M., Meesters, M. I., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx325 · Cited by 481
Self-citation2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Boer, C., Meesters, M. I., Milojevic, M., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.026 · Cited by 466
Self-citationThe Inflammatory Response to Cardiopulmonary Bypass: Part 1—Mechanisms of Pathogenesis
Warren, O. J., Smith, A. J., Alexiou, C., Rogers, P. L. B., Jawad, N., Vincent, C., Darzi, A. W., & Athanasiou, T. (2009) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2008.08.007 · Cited by 363
The chemistry of snake venom and its medicinal potential
Oliveira, A. L., Viegas, M. F., da Silva, S. L., Soares, A. M., Ramos, M. J., & Fernandes, P. A. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00393-7 · Cited by 289
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Metadata
- Authors
- Greinacher, A., Koster, A., & Warkentin, T.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2008
- Volume
- 99
- Issue
- 11
- Pages
- 830-839
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W4238696256
- Cited by
- 163
- References
- 0
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bivalirudin. https://app.cochat.ai/papers/10.1160/th07-10-0644
- The paper
- Greinacher, A., Koster, A., & Warkentin, T. (2008). Bivalirudin. Thrombosis and Haemostasis. https://doi.org/10.1160/th07-10-0644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.